Transiently increased circulating CD39+FoxP3+ Treg cells predicts the clinical response to methotrexate in early rheumatoid arthritis
Authors' conclusion
MTX cooperates with Treg39+ cells and the baseline cTreg39+ frequency predicts the response to MTX in eRA.
Study context
- Population
- Untreated early RA patients initiating methotrexate (MTX) and healthy controls82 re-evaluated at 12 m
- Exposure
- Untreated early rheumatoid arthritis (eRA) patients vs healthy controls (HC); patients reaching 12 m-LDA on MTX vs those not
- Outcome
- Relation of baseline circulating CD39+FoxP3+ Treg (cTreg39+) frequency to LDA (DAS28-ESR ≤ 3.2) on MTX
- Follow-up
- 12 months
Methodological detailsin vitro Treg/Tresp cocultures
- In vitro Treg/Tresp cocultures
Main finding
As reported in the abstract
Baseline cTreg39+ frequency predicting 12 m-LDA · 0 m
| Group | Value | Cutoff | Sensitivity | Specificity |
|---|---|---|---|---|
| 12 m-LDA | 42.0% | 42.0% | 90.4% | 96.8% |
12 m-LDA
Value42.0%
Cutoff42.0%
Sensitivity90.4%
Specificity96.8%
Observational data: associations, not effects.
Further findings
cTreg39+ frequency at 12 m
- No longer elevated; still significantly higher in patients reaching LDA vs not
- Cytometry repeated in 40 patients
In vitro Treg potency with MTX
- MTX augmented Treg39+ cell potency; no effect on Treg39- cells
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Transiently increased circulating CD39+FoxP3+ Treg cells predicts the clinical response to methotrexate in early rheumatoid arthritis. Rheumatology (Oxford). Published 14 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →